Vedolizumab for the treatment of Crohn’s disease

Marjorie Argollo, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese

Research output: Contribution to journalArticle

Abstract

Introduction: Crohn’s disease (CD) is an immune-mediated condition characterized by inflammation of the gut tissue, associated with progressive damage of the affected intestinal tract and possible complications. A treat-to-target approach is strongly advocated, consisting of early and aggressive inflammatory control. However, a great proportion of affected subjects lack response or are intolerant to conventional therapy. Even though the first-line biologic therapy targeting tumor necrosis factor-alfa (TNF-α) is associated with improvement of inflammation in some patients, others do not respond at first or lose response over time. These findings brought about the possibility of different mechanisms being involved in perpetuating the chronic inflammatory state. Novel drugs targeting different inflammatory pathways have been studied in CD, specifically addressed to leucocyte trafficking. Areas covered: We aim to review the relevant data available in the literature and briefly summarize the efficacy and safety profile of vedolizumab in the treatment of CD. Expert commentary: Vedolizumab has shown, from pivotal and real-life data, significant clinical benefit among CD patients, in addition to a singular safety profile. Future studies will provide helpful data concerning its use in special situations.

Original languageEnglish
Pages (from-to)179-189
Number of pages11
JournalExpert Review of Clinical Immunology
Volume14
Issue number3
DOIs
Publication statusPublished - Mar 4 2018

Fingerprint

Crohn Disease
Inflammation
Safety
Biological Therapy
Therapeutics
Drug Delivery Systems
Leukocytes
Tumor Necrosis Factor-alpha
vedolizumab

Keywords

  • biologics
  • Crohn’s disease
  • Inflammatory bowel disease
  • treatment
  • vedolizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Vedolizumab for the treatment of Crohn’s disease. / Argollo, Marjorie; Fiorino, Gionata; Peyrin-Biroulet, Laurent; Danese, Silvio.

In: Expert Review of Clinical Immunology, Vol. 14, No. 3, 04.03.2018, p. 179-189.

Research output: Contribution to journalArticle

Argollo, Marjorie ; Fiorino, Gionata ; Peyrin-Biroulet, Laurent ; Danese, Silvio. / Vedolizumab for the treatment of Crohn’s disease. In: Expert Review of Clinical Immunology. 2018 ; Vol. 14, No. 3. pp. 179-189.
@article{bf6bda554c17461f8c9e1db603eac18b,
title = "Vedolizumab for the treatment of Crohn’s disease",
abstract = "Introduction: Crohn’s disease (CD) is an immune-mediated condition characterized by inflammation of the gut tissue, associated with progressive damage of the affected intestinal tract and possible complications. A treat-to-target approach is strongly advocated, consisting of early and aggressive inflammatory control. However, a great proportion of affected subjects lack response or are intolerant to conventional therapy. Even though the first-line biologic therapy targeting tumor necrosis factor-alfa (TNF-α) is associated with improvement of inflammation in some patients, others do not respond at first or lose response over time. These findings brought about the possibility of different mechanisms being involved in perpetuating the chronic inflammatory state. Novel drugs targeting different inflammatory pathways have been studied in CD, specifically addressed to leucocyte trafficking. Areas covered: We aim to review the relevant data available in the literature and briefly summarize the efficacy and safety profile of vedolizumab in the treatment of CD. Expert commentary: Vedolizumab has shown, from pivotal and real-life data, significant clinical benefit among CD patients, in addition to a singular safety profile. Future studies will provide helpful data concerning its use in special situations.",
keywords = "biologics, Crohn’s disease, Inflammatory bowel disease, treatment, vedolizumab",
author = "Marjorie Argollo and Gionata Fiorino and Laurent Peyrin-Biroulet and Silvio Danese",
year = "2018",
month = "3",
day = "4",
doi = "10.1080/1744666X.2018.1438189",
language = "English",
volume = "14",
pages = "179--189",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Vedolizumab for the treatment of Crohn’s disease

AU - Argollo, Marjorie

AU - Fiorino, Gionata

AU - Peyrin-Biroulet, Laurent

AU - Danese, Silvio

PY - 2018/3/4

Y1 - 2018/3/4

N2 - Introduction: Crohn’s disease (CD) is an immune-mediated condition characterized by inflammation of the gut tissue, associated with progressive damage of the affected intestinal tract and possible complications. A treat-to-target approach is strongly advocated, consisting of early and aggressive inflammatory control. However, a great proportion of affected subjects lack response or are intolerant to conventional therapy. Even though the first-line biologic therapy targeting tumor necrosis factor-alfa (TNF-α) is associated with improvement of inflammation in some patients, others do not respond at first or lose response over time. These findings brought about the possibility of different mechanisms being involved in perpetuating the chronic inflammatory state. Novel drugs targeting different inflammatory pathways have been studied in CD, specifically addressed to leucocyte trafficking. Areas covered: We aim to review the relevant data available in the literature and briefly summarize the efficacy and safety profile of vedolizumab in the treatment of CD. Expert commentary: Vedolizumab has shown, from pivotal and real-life data, significant clinical benefit among CD patients, in addition to a singular safety profile. Future studies will provide helpful data concerning its use in special situations.

AB - Introduction: Crohn’s disease (CD) is an immune-mediated condition characterized by inflammation of the gut tissue, associated with progressive damage of the affected intestinal tract and possible complications. A treat-to-target approach is strongly advocated, consisting of early and aggressive inflammatory control. However, a great proportion of affected subjects lack response or are intolerant to conventional therapy. Even though the first-line biologic therapy targeting tumor necrosis factor-alfa (TNF-α) is associated with improvement of inflammation in some patients, others do not respond at first or lose response over time. These findings brought about the possibility of different mechanisms being involved in perpetuating the chronic inflammatory state. Novel drugs targeting different inflammatory pathways have been studied in CD, specifically addressed to leucocyte trafficking. Areas covered: We aim to review the relevant data available in the literature and briefly summarize the efficacy and safety profile of vedolizumab in the treatment of CD. Expert commentary: Vedolizumab has shown, from pivotal and real-life data, significant clinical benefit among CD patients, in addition to a singular safety profile. Future studies will provide helpful data concerning its use in special situations.

KW - biologics

KW - Crohn’s disease

KW - Inflammatory bowel disease

KW - treatment

KW - vedolizumab

UR - http://www.scopus.com/inward/record.url?scp=85042441968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042441968&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2018.1438189

DO - 10.1080/1744666X.2018.1438189

M3 - Article

C2 - 29406811

AN - SCOPUS:85042441968

VL - 14

SP - 179

EP - 189

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 3

ER -